Oculus Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 1.34 M
- Company Age 43 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
About Oculus Pharmaceuticals
Oculus Pharmaceuticals Private Limited (OPPL) is a Private Limited Indian Non-Government Company incorporated in India on 05 March 1981 and has a history of 43 years and 11 months. Its registered office is in Uttar Pradesh, Uttar Pradesh.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.34 M, as per Ministry of Corporate Affairs (MCA) records.
Ram Ram, Alok Singh, Krishan Srivastva, and Two other members serve as directors at the Company.
Company Details
- Location Uttar Pradesh, Uttar Pradesh
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24231UP1981PTC005219
-
Company No.
005219
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
05 Mar 1981
-
Date of AGM
26 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
What products or services does Oculus Pharmaceuticals Private Limited offer?
Oculus Pharmaceuticals Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules, Common Disease Medicines, Ointment, Pharmaceutical Tablets, Eye Drops, Anti Infective Drugs & Medicines, Anti Infective Agent.
Who are the key members and board of directors at Oculus Pharmaceuticals?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ram Ram
|
Director | 05-Mar-1981 | Current |
|
Alok Singh
|
Director | 22-Feb-2010 | Current |
|
Krishan Srivastva
|
Director | 22-Feb-2010 | Current |
|
Meenakshi Singh
|
Director | 22-Feb-2010 | Current |
| Shakuntala Srivastava | Director | 21-Oct-2024 | Current |
Financial Performance of Oculus Pharmaceuticals.
Oculus Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Oculus Pharmaceuticals?
In 2017, Oculus Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Oculus Pharmaceuticals?
Unlock and access historical data on people associated with Oculus Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Oculus Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Oculus Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
